Page last updated: 2024-10-26

dipyridamole and Experimental Radiation Injuries

dipyridamole has been researched along with Experimental Radiation Injuries in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hornsey, S1
Myers, R1
Jenkinson, T1

Other Studies

1 other study available for dipyridamole and Experimental Radiation Injuries

ArticleYear
The reduction of radiation damage to the spinal cord by post-irradiation administration of vasoactive drugs.
    International journal of radiation oncology, biology, physics, 1990, Volume: 18, Issue:6

    Topics: Animals; Deferoxamine; Dipyridamole; Male; Necrosis; Radiation Injuries, Experimental; Rats; Reperfu

1990